Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Our Plans

Compare everything

See all plans, pricing and what each product includes side by side.

Plans & Subscriptions

Explore

Analyst Notes

Stocks – Q : Quality | V : Valuation | PT : Price Trend
Funds – P : Performance | Q : Quality

Top Pharma Companies in India by Market Cap

BSE Sensex 76941.61
105.83 (0.14%)

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Metropolis Healthcare Ltd.	Q V PT	11,981 Small Cap	592.35 (2.53%)	63.05	7.92	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,882.80 (-1.22%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Wanbury Ltd.	Q V+ PT	1,157 Small Cap	318.45 (-3.85%)	17.5	8.01	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,815 Small Cap	2,651 (-2.29%)	41.8	8.47	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Krishna Institute of Medical Sciences Ltd	Q V PT	33,598 Small Cap	791.10 (-1.11%)	128.88	8.55	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Senores Pharmaceuticals Ltd.	Q V+ PT	6,500 Small Cap	1,318.70 (-6.57%)	349.68	8.67	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Rainbow Childrens Medicare Ltd.	Q V PT	15,076 Small Cap	1,471 (-0.90%)	60.3	8.95	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Narayana Hrudayalaya Ltd.	Q V PT	41,974 Mid Cap	2,070.80 (0.82%)	52.1	9.25	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Panacea Biotec Ltd.	Q V+ PT	2,654 Small Cap	418.10 (-3.51%)	N/A	9.3	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Ajanta Pharma Ltd.	Q V+ PT	42,278 Mid Cap	3,346.65 (-1.10%)	40.04	9.35	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Global Health Ltd.	Q V PT	37,844 Small Cap	1,405.80 (-0.12%)	76.27	9.41	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Emcure Pharmaceuticals Ltd.	Q V+ PT	36,490 Small Cap	1,945.55 (1.13%)	49.78	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,376.85 (0.23%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Max Healthcare Institute Ltd.	Q V PT	1,08,476 Mid Cap	1,114 (-0.05%)	75.2	10.23	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Sai Life Sciences Ltd.	Q V+ PT	27,347 Small Cap	1,293.50 (0.42%)	80.08	10.9	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Divis Laboratories Ltd.	Q V+ PT	1,96,881 Large Cap	7,451.30 (0.47%)	76.67	11.75	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Dr. Lal Pathlabs Ltd.	Q V PT	30,607 Small Cap	1,813.55 (-0.67%)	56.18	11.9	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Abbott India Ltd.	Q V PT	59,102 Mid Cap	27,893.35 (0.29%)	38.08	12.45	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,27,149 Large Cap	8,883 (0.45%)	85.19	12.76	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Neuland Laboratories Ltd.	Q V+ PT	24,345 Small Cap	18,887 (-0.47%)	67.05	13.05	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,930 Small Cap	356.25 (-1.22%)	84.18	13.66	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Anthem Biosciences Ltd.	Q V PT	44,516 Mid Cap	780 (-1.28%)	71.31	13.68	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Park Medi World Ltd.	Q V+ PT	12,060 Small Cap	279.20 (0.00%)	329.35	14.02	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Aster DM Quality Care Ltd.	Q V+ PT	70,000 Mid Cap	803.50 (0.06%)	180.35	14.2	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Vijaya Diagnostic Centre Ltd.	Q V PT	13,894 Small Cap	1,347 (-0.14%)	80.32	14.52	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Thyrocare Technologies Ltd.	Q V+ PT	9,287 Small Cap	592.20 (1.49%)	52.68	14.76	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Acutaas Chemicals Ltd.	Q V+ PT	27,579 Small Cap	3,109.85 (-7.68%)	69.39	15.81	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Laurus Labs Ltd.	Q V+ PT	92,623 Mid Cap	1,745.85 (1.84%)	84.7	16.43	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	CORONA Remedies Ltd.	Q V+ PT	12,807 Small Cap	2,092.45 (-0.08%)	69.28	17.17	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	43,202 Mid Cap	2,574.05 (0.94%)	41.7	18.92	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.25	3.23%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	592.35	2.53%
Fabtech Technologies	152.35	2.49%
Laurus Labs	1,745.85	1.84%

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,109.85	-7.68%
Senores Pharmaceutic	1,318.70	-6.57%
Suven Life Sciences	298.90	-4.11%
Wanbury	318.45	-3.85%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

Anthem Biosciences informs about transcript of conference call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ?4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Rank	Company	Market Capitalization 2026 (INR crores)
1	KMC Speciality Hospitals (India) Ltd.	2,127 Crore
2	Nectar Lifesciences Ltd.	202 Crore
3	Dishman Carbogen Amcis Ltd.	2,922 Crore
4	Shalby Ltd.	1,783 Crore
5	Unichem Laboratories Ltd.	3,826 Crore
6	Lincoln Pharmaceuticals Ltd.	1,163 Crore
7	Fabtech Technologies Ltd.	661 Crore
8	Krsnaa Diagnostics Ltd.	1,758 Crore
9	Natco Pharma Ltd.	16,606 Crore
10	Solara Active Pharma Sciences Ltd.	2,439 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,629	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,551	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,586	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,983	4,73,509	41.25	5.67	23.65	14.41

About MoneyWorks4Me

*Color code for outperformance consistency

*Number is average 3 year rolling returns

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

Anthem Biosciences informs about transcript of conference call

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Laurus Labs - Quaterly Results

Panacea Biotec informs about disclosure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

Anthem Biosciences informs about transcript of conference call

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Laurus Labs - Quaterly Results

Panacea Biotec informs about disclosure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.